세계의 혈소판 응집 기기 시장 : 제품 유형별, 용도별, 최종 용도별 예측(2024-2032년)

Platelet Aggregation Devices Market size is expected to grow at over 8.9% CAGR during 2024-2032, driven by the strong demand for personalized medicine, escalating R&D activities, and increasing healthcare expenditure. Cardiovascular diseases (CVDs) continue to be a leading cause of mortality worldwide, holding a substantial burden on healthcare systems. According to American College of Cardiology, the global death toll from cardiovascular diseases surged from 12.4 million in 1990 to 19.8 million in 2022. Sedentary lifestyles, unhealthy dietary habits, and increasing geriatric population are adding to the escalating incidence of CVDs globally.

Platelet aggregation devices play a crucial role in diagnosing and monitoring various cardiovascular conditions, including thrombosis, myocardial infarction, and stroke. As healthcare providers strive to enhance patient care and improve outcomes, there is a growing demand for advanced diagnostic tools capable of detecting platelet dysfunction and assessing thrombotic risk accurately.

The platelet aggregation devices market is classified into product type, application, end-use and region.

Based on product type, the industry size from the reagents segment is expected to grow at 8.5% CAGR from 2024 to 2032, owing to their role in platelet aggregation testing to facilitate the detection and quantification of platelet aggregation responses. These reagents include agonists, such as adenosine diphosphate (ADP), arachidonic acid, and collagen, which activate platelet receptors and induce platelet aggregation. Furthermore, the development of novel reagents with enhanced specificity and sensitivity is driving innovations in platelet aggregation devices, enabling clinicians to tailor treatment regimens based on individual patient profiles and optimize therapeutic outcomes.

In terms of application, the platelet aggregation devices industry from the research segment is poised to record 8.6% CAGR up to 2032. Researchers are increasingly utilizing platelet aggregation devices to investigate the mechanisms underlying thrombosis, hemostasis, and platelet dysfunction, paving the way for the development of novel therapeutic targets and interventions. Moreover, the integration of platelet aggregation testing into translational research studies and clinical trials is facilitating the identification of biomarkers for disease prognosis and treatment response, further driving the segment growth.

Asia Pacific platelet aggregation devices industry is set to gain traction at 10.6% CAGR till 2032, fueled by rapid urbanization, aging population, and increasing healthcare expenditure. Countries, such as China, India, and Japan are witnessing a surge in the prevalence of cardiovascular diseases, further driving the demand for advanced diagnostic and monitoring solutions. The presence of a large patient pool and growing awareness about preventive healthcare measures are also creating favorable conditions for the adoption of platelet aggregation devices in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Technological advancements in platelet aggregometers
    • 3.2.1.3 Growing patient population related to cardiovascular diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of devices and shortage of skilled personnel
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Systems
• 5.3 Reagents
• 5.4 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Research applications
• 6.3 Clinical applications
  • 6.3.1 Cardiovascular applications
  • 6.3.2 Orthopedic applications
  • 6.3.3 Other clinical applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Research and academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AggreDyne, Inc.
• 9.2 Bio/Data Corporation
• 9.3 Chrono-Log Corporation
• 9.4 Drucker Diagnostics
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 Haemonetics Corporation
• 9.7 Helena Laboratories Corporation
• 9.8 Siemens Healthineers AG
• 9.9 Sienco, Inc.
• 9.10 Sysmex Corporation
• 9.11 Werfen